147 related articles for article (PubMed ID: 20165991)
1. Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study.
Chen Z; Du Z; Chen J; Chen Z; Bao Y; Tang F
Med Oncol; 2011 Mar; 28(1):241-8. PubMed ID: 20165991
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
[TBL] [Abstract][Full Text] [Related]
4. Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy.
Hassan U; Mushtaq S; Mamoon N; Asghar AH; Ishtiaq S
Asian Pac J Cancer Prev; 2012; 13(4):1341-7. PubMed ID: 22799329
[TBL] [Abstract][Full Text] [Related]
5. [Significance of CD138 in immunohistochemical profiles and its correlation with prognosis in diffuse large B-cell lymphoma].
Zhang HW; Chen ZW; Wang JF; Cheng NL
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):115-20. PubMed ID: 21575479
[TBL] [Abstract][Full Text] [Related]
6. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
7. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
8. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
9. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
[TBL] [Abstract][Full Text] [Related]
10. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
11. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation.
Song Y; Cao Z; Li L; Zhang HT; Zhang X
Chin J Cancer; 2010 Sep; 29(9):781-6. PubMed ID: 20800019
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
13. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma.
Hallack Neto AE; Siqueira SA; Dulley FL; Chauobah A; Belesso M; Saboia R; Ruiz MA; Chamone DA; Pereira J
Sao Paulo Med J; 2010 Jan; 128(1):14-7. PubMed ID: 20512275
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.
Anderson JJ; Fordham S; Overman L; Dignum H; Wood K; Proctor SJ; Crosier S; Angus B; Culpin RE; Mainou-Fowler T
Int J Oncol; 2009 Nov; 35(5):961-71. PubMed ID: 19787248
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
Oh S; Koo DH; Suh C; Kim S; Park BH; Kang J; Huh J
J Korean Med Sci; 2011 Dec; 26(12):1556-62. PubMed ID: 22147991
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia.
Peh SC; Gan GG; Lee LK; Eow GI
Pathol Int; 2008 Sep; 58(9):572-9. PubMed ID: 18801072
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
Ichiki A; Carreras J; Miyaoka M; Kikuti YY; Jibiki T; Tazume K; Watanabe S; Sasao T; Obayashi Y; Onizuka M; Ohmachi K; Yoshiba F; Shirasugi Y; Ogawa Y; Kawada H; Nakamura N; Ando K
J Clin Exp Hematop; 2017; 57(2):54-63. PubMed ID: 29021515
[TBL] [Abstract][Full Text] [Related]
19. The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas.
Rayman N; Lam KH; van der Holt B; Koss C; van Leeuwen J; Budel LM; Mulder AH; Sonneveld P; Delwel R
Eur J Haematol; 2011 Jun; 86(6):466-76. PubMed ID: 21457344
[TBL] [Abstract][Full Text] [Related]
20. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients.
Amen F; Horncastle D; Elderfield K; Banham AH; Bower M; Macdonald D; Kanfer E; Naresh KN
Histopathology; 2007 Jul; 51(1):70-9. PubMed ID: 17593082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]